Triple threat: new combo therapy targets Hard-to-Treat stomach cancer
NCT ID NCT07502027
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This clinical trial is testing a new approach for people with advanced HER2-negative stomach or gastroesophageal junction cancer that cannot be removed by surgery. The treatment combines two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy (SOX) and a special type of radiation therapy. The study aims to see if this combination can shrink tumors and improve outcomes. It will enroll 55 participants across multiple centers in China.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Iparomlimab and tuvonralimab (dual immunotherapy) plus SOX chemotherapy (S-1 and oxaliplatin) and heterogeneous radiotherapy
- What this could lead to
- If successful, this combination could offer a new first-line treatment option for people with advanced HER2-negative gastric cancer, potentially improving tumor shrinkage and survival.
- What could go wrong
- This is an early, single-arm study with only 55 participants, so results may not apply broadly. Combining immunotherapy, chemotherapy, and radiation also raises the risk of significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can an immunotherapy combo shrink stomach tumors before surgery?
- Can adding immunotherapy to chemotherapy improve gastric cancer outcomes?
- Can immunotherapy outperform chemo after stomach cancer surgery?
- Can a smart drug home in on Hard-to-Treat cancers?